Factor Model (net -2.1)
Factor Model
net -2.1 4.7 / 10Esperion locks in generic exclusivity through 2040
Watch: Pipeline execution under Vision 2040 — the company needs to deliver at least three new approvals to justify a five-product portfolio claim. Next catalysts: regulatory approvals, Phase 2/3 readout timing, and whether revenue sustains its 35%+ growth rate through 2026.
Esperion secured a deal with Alkem Laboratories on February 17 to block generic competition for its two core drugs — NEXLETOL and NEXLIZET — until April 2040. This follows similar agreements with Dr. Reddy's and at least three other manufacturers announced in January. The company's 2025 preliminary US sales hit $156–$160 million, a 35–38% jump year-over-year, with management eyeing a Vision 2040 roadmap targeting five products on market.
Locking out generics until 2040 gives Esperion a 14-year runway to grow its cardiometabolic franchise without price erosion — a massive structural advantage for a micro-cap biotech. Revenue growth already accelerating, but the real value is exclusivity: drugs with protected franchises trade at much higher multiples than those facing near-term generic cliffs.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when ESPR changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.